Top Page
The United Laboratories International Holdings
(OTC:3933)
The United Laboratories International Holdings (3933) vs. iShares MSCI Hong Kong ETF (EWH)
The United Laboratories International Holdings Business Overview & Revenue Model
The United Laboratories International Holdings Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.76B | 13.74B | 11.33B | 9.70B | 8.77B |
| Gross Profit | 6.08B | 6.33B | 4.97B | 4.21B | 3.81B |
| EBITDA | 3.35B | 3.98B | 2.54B | 1.98B | 1.83B |
| Net Income | 2.66B | 2.70B | 1.58B | 988.10M | 702.99M |
Balance Sheet | |||||
| Total Assets | 25.83B | 21.02B | 18.98B | 16.33B | 14.96B |
| Cash, Cash Equivalents and Short-Term Investments | 6.33B | 4.26B | 4.74B | 3.33B | 3.00B |
| Total Debt | 3.16B | 1.50B | 2.46B | 1.84B | 2.21B |
| Total Liabilities | 11.40B | 8.27B | 8.37B | 6.99B | 6.35B |
| Stockholders Equity | 14.39B | 12.73B | 10.61B | 9.34B | 8.61B |
Cash Flow | |||||
| Free Cash Flow | 1.33B | 977.50M | 1.25B | 1.06B | 1.04B |
| Operating Cash Flow | 3.20B | 2.44B | 2.03B | 1.54B | 1.57B |
| Investing Cash Flow | -1.73B | -1.56B | -594.92M | -587.22M | 166.76M |
| Financing Cash Flow | 596.91M | -1.36B | -24.17M | -620.93M | -1.91B |
The United Laboratories International Holdings Technical Analysis
The United Laboratories International Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$33.15B | 13.25 | 15.61% | 2.78% | 10.59% | 31.83% | |
75 Outperform | HK$27.40B | 9.69 | 19.62% | 4.68% | -1.82% | -3.34% | |
74 Outperform | $39.16B | 15.17 | 14.56% | 3.24% | -5.37% | 6.28% | |
71 Outperform | $31.86B | 18.38 | 10.17% | 5.02% | -8.91% | -34.40% | |
62 Neutral | €33.30B | 9.29 | 6.85% | ― | ― | ||
60 Neutral | £23.46B | 81.41 | 5.02% | ― | -25.07% | -64.03% | |
52 Neutral | $7.47B | -0.04 | -63.86% | 2.34% | 16.17% | 0.25% |
The United Laboratories International Holdings Corporate Events
The United Laboratories International Holdings Limited has announced a placing of new shares under a general mandate, aiming to raise approximately HK$2,168.2 million in net proceeds. The funds will be allocated towards capital expenditure for expanding manufacturing facilities, enhancing external collaborations, and research and development, including clinical trials for innovative product candidates.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced that its product, Amoxicillin Sodium and Clavulanate Potassium for Injection, has passed the Consistency Evaluation by the China National Medical Products Administration. This approval is expected to strengthen the company’s position in the anti-infective field and enhance its market presence, while continuing to focus on research and development for future growth.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced the FDA approval of its investigational new drug application for UBT37034 Injection, a Class 1 innovative drug targeting overweight and obesity. This approval marks a significant step for the company in enhancing its competitiveness and creativity within the biopharmaceutical industry, potentially benefiting its operations and stakeholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced a final cash dividend of RMB 0.28 per share for the financial year ending December 31, 2024. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.094945, with a payment date set for July 23, 2025. This announcement reflects the company’s stable financial performance and commitment to returning value to its shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited has announced a special dividend of RMB 0.12 per share for the financial year ending 31 December 2024, with payment to be made in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.094945. This announcement reflects the company’s strong financial performance and commitment to providing value to its shareholders, with the payment date set for 23 July 2025.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced the approval of a final dividend of RMB28 cents per share and a special dividend of RMB12 cents per share for the year ending December 31, 2024. These dividends will be converted to Hong Kong dollars and are expected to be paid on July 23, 2025, to shareholders listed on the register as of July 11, 2025. This announcement reflects the company’s commitment to rewarding its shareholders and could positively impact its market positioning by enhancing shareholder value.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced that all proposed resolutions at their 2025 Annual General Meeting were approved by shareholders. Key resolutions included the adoption of financial statements, declaration of dividends, re-election of directors, and granting of mandates related to company securities. This successful AGM reflects shareholder confidence and supports the company’s strategic direction.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced that its subsidiary, United Biotechnology, has received an upfront payment of $180 million from Novo Nordisk under an exclusive license agreement for UBT251, a triple agonist in clinical trials for obesity and type 2 diabetes. This agreement also allows United Biotechnology to potentially receive up to $1.8 billion in milestone payments and tiered royalties based on future sales, highlighting a significant financial and strategic boost for the company in the pharmaceutical sector.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 25, 2025. Key agenda items include the adoption of financial statements, declaration of final and special dividends, re-election of directors, and the re-appointment of Deloitte Touche Tohmatsu as auditors. The meeting will also consider a resolution to authorize the board to allot and issue additional shares, reflecting the company’s strategic focus on growth and shareholder value.